Biomedical Engineering Reference
In-Depth Information
Table
1.2
Examples
of
high
molecular
weight
(.100
kDa)
systems
studied
using
methyl-specific
labelling
and
NMR
spectroscopy.
Oligomeric state
a
b
Size/kDa
Protein
Year
Label
NMR studies performed
Ref.
9 or 10
c
61
130
FAS-FADD
2010
(FAS
4/5
-FADD
5
)
I/LV
Analysis of complex formation
29
203
SecA
2007
4 (SecA
2
-SP
2
)
M/I/LV
PRE-derived structural model of SecA:
peptide complex
62
210
Hsp90-p23
2011
4 (Hsp90
2
-p23
2
)
I
Mapping ATP and p23 binding sites on Hsp90
63
230
nucleosome
2011
(H2A, H2B, H3
2
, H4
2
, DNA)
ILV
Interaction between histones and regulatory
proteins
48
300
ClpP
2005
14
I
Conformational exchange and substrate release
60
300
ATCase
2007
12 (r
6
c
6
)
I/LV
Characterising allosteric states and co-
operative binding
26
306
p97 ND1
2011
6 (+1)
A
Mapping protein-protein interactions
Acquisition of 2D (
1
H,
13
C) Methyl-TROSY
spectra in , 1s
23
468
TET2
2009
12
A/I
L
S
V
S
44
2010
Monitoring of interactions with inhibitor
27
2011
A/I
Semi-automated
assignment-by-mutagenesis
64
560
aB-crystallin
2011
I/LV
Examination of oligomeric polydispersity
45
670
Proteasome
2007
28 (a
7
b
7
b
7
a
7
)
I/LV
Complex assembly, ligand binding, methyl
group dynamics
32
2010
M
Dynamics and role of N-termini in
Proteasome gating
65
2010
I/LV
Monitoring of interactions with substrate
proteins
45
1000
Proteasome-activatior
2007
40 (a
7
b
7
b
7
a
7
, 11S)
I/LV
Mapping proteasome-activator interaction
surface
a
Number of subunits and composition. In the case of hetero-oligomers bold font indicates the subunit labelled in the study.
b
M 5 [e-
13
CH
3
]methione; I 5
[d
1
-
13
CH
3
]isoleucine using a-ketobutyrate; LV 5 [
13
CH
3
/
12
CD
3
]leucine, valine using a-ketoisovalerate; LSVS 5 [pro-(S)
13
CH
3
/pro-(R)
12
CD
3
]leucine, valine using
acetolactate; A 5 [b-
13
CH
3
]alanine.
c
Exact composition of complex in solution not currently known.
